文献速递核素与放射性配体治疗

肿瘤灌注与受体密度对177Lu-DOTATATE治疗肿瘤控制概率的影响:标准与优化治疗的计算机模拟分析

Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in 177Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized Treatment.
PubMed 文献 · J Nucl Med · 2020-07-09

该研究采用生理基于药代动力学(PBPK)模型,对9例虚拟患者模拟不同肿瘤灌注和受体密度组合下177Lu-DOTATATE治疗的肿瘤控制概率(TCP)。结果显示,标准治疗达到99% TCP所需最小肿瘤灌注为0.036±0.023 mL/g/min、受体密度为34±20 nmol/L;优化周期数或配体量/活度可降低这些阈值,其中177Lu从肿瘤细胞释放速率影响最强。

要点

  • 标准方案达99%TCP需最小灌注0.036±0.023 mL/g/min、受体密度34±20 nmol/L。
  • 优化周期数后阈值降至灌注0.022±0.012 mL/g/min、受体密度21±11 nmol/L。
  • 优化配体量与活度后阈值更低:灌注0.018±0.009 mL/g/min、受体密度18±10 nmol/L。

核心结论

  • PBPK建模可个体化确定达到足够TCP所需的最小肿瘤灌注和最小受体密度。

研究设计与样本

  • 使用近期开发的PBPK模型,基于9例虚拟患者(个体化PBPK模型)模拟不同灌注(0.001-0.1 mL/g/min)和受体密度(1-100 nmol/L)组合的药代动力学。

主要发现

  • 标准治疗(4周期7.4 GBq和105 nmol)达到至少99% TCP所需最小肿瘤灌注为0.036±0.023 mL/g/min、受体密度为34±20 nmol/L(9例虚拟患者)。
  • 基于红骨髓和肾脏BEDmax最大化周期数的治疗,最小灌注和受体密度分别为0.022±0.012 mL/g/min和21±11 nmol/L。
  • 4周期优化配体量和活度的治疗,最小灌注和受体密度分别为0.018±0.009 mL/g/min和18±10 nmol/L。
  • 177Lu(或标记代谢物)从肿瘤细胞的释放速率对标准和优化治疗的最小灌注和受体密度影响最强。

关键数值与推荐

  • 红骨髓BEDmax假定为2 Gy15,肾脏BEDmax假定为40 Gy2.5。
  • 标准治疗为4周期7.4 GBq和105 nmol。

临床怎么用

  • 该方法可用于放射性药物研发中针对特定肿瘤类型的配体和靶点选择。
  • 该方法可用于优化临床试验设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this work was to determine a minimal tumor perfusion and receptor density for 177Lu-DOTATATE therapy using physiologically based pharmacokinetic (PBPK) modeling considering, first, a desired tumor control probability (TCP) of 99% and, second, a maximal tolerated biologically effective dose (BEDmax) for organs at risk (OARs) in the treatment of neuroendocrine tumors and meningioma. Methods: A recently developed PBPK model was used. Nine virtual patients (i.e., individualized PBPK models) were used to perform simulations of pharmacokinetics for different combinations of perfusion (0.001-0.1 mL/g/min) and receptor density (1-100 nmol/L). The TCP for each combination was determined for 3 different treatment strategies: a standard treatment (4 cycles of 7.4 GBq and 105 nmol), a treatment maximizing the number of cycles based on BEDmax for red marrow and kidneys, and a treatment having 4 cycles with optimized ligand amount and activity. The red marrow and the kidneys (BEDmax of 2 Gy15 and 40 Gy2.5, respectively) were assumed to be OARs. Additionally, the influence of varying glomerular filtration rates, kidney somatostatin receptor densities, tumor volumes, and release rates was investigated. Results: To achieve a TCP of at least 99% in the standard treatment, a minimal tumor perfusion of 0.036 ± 0.023 mL/g/min and receptor density of 34 ± 20 nmol/L were determined for the 9 virtual patients. With optimization of the number of cycles, the minimum values for perfusion and receptor density were considerably lower, at 0.022 ± 0.012 mL/g/min and 21 ± 11 nmol/L, respectively. However, even better results (perfusion, 0.018 ± 0.009 mL/g/min; receptor density, 18 ± 10 nmol/L) were obtained for strategy 3. The release rate of 177Lu (or labeled metabolites) from tumor cells had the strongest effect on the minimal perfusion and receptor density for standard and optimized treatments. Conclusion: PBPK modeling and simulations represent an elegant approach to individually determine the minimal tumor perfusion and minimal receptor density required to achieve an adequate TCP. This computational method can be used in the radiopharmaceutical development process for ligand and target selection for specific types of tumors. In addition, this method could be used to optimize clinical trials.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Jiménez-Franco LD, Glatting G, Prasad V, et al. Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in 177Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized Treatment. J Nucl Med. 2020. PMID: 32646878. doi:10.2967/jnumed.120.245068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。